NCT06855758 Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation
| NCT ID | NCT06855758 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Friendship Hospital |
| Condition | Kidney Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2025-03-06 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2025-03-06 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective double blind randomized controlled trial. By randomizing patients undergoing kidney transplantation into a conventional catecholamine drug (dobutamine) blood pressure maintenance group and a terlipressin-complexed dobutamine group, the investigators compared the effect of intraoperative blood pressure maintenance and the dosage of the vasoactive drug, postoperative graft function, delayed graft function, and other related complications between the two groups, in order to demonstrate whether the use of terlipressin for blood pressure regulation during kidney transplantation is superior to the existing treatments.
Eligibility Criteria
Inclusion Criteria: * Patients with end-stage renal disease aged 18 years or above Exclusion Criteria: * simultaneous multiple organ transplantation * known allergy to study medication * known pregnancy status * cancellation of surgery due to grafts or personal reasons * persistent severe preoperative hypertension that may not require intraoperative supportive therapy with vasoactive medications * any other reason that the supervising physician or the anesthesiologist on duty think the patient is not suitable for the study
Contact & Investigator
Fushan Xue
PRINCIPAL INVESTIGATOR
Department of Anesthesiology, Beijing Friendship Hospital
Frequently Asked Questions
Who can join the NCT06855758 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Kidney Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06855758 currently recruiting?
Yes, NCT06855758 is actively recruiting participants. Contact the research team at 13810673664@163.com for enrollment information.
Where is the NCT06855758 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06855758 clinical trial?
NCT06855758 is sponsored by Beijing Friendship Hospital. The principal investigator is Fushan Xue at Department of Anesthesiology, Beijing Friendship Hospital. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.